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Background: Amyotrophic lateral sclerosis (ALS) is a devastating late onset neurodegenerative disorder that is
characterised by the progressive loss of upper and lower motor neurons. The mechanisms underlying ALS
pathogenesis are unclear; however, there is emerging evidence the innate immune system, including components
of the toll-like receptor (TLR) system, may drive disease progression. For example, toll-like receptor 4 (TLR4) antagonism
in a spontaneous ‘wobbler mouse’ model of ALS increased motor function, associated with a decrease in microglial
activation. This study therefore aimed to extend from these findings and determine the expression and function of
TLR4 signalling in hSOD1G93A mice, the most widely established preclinical model of ALS.
Findings: TLR4 and one of its major endogenous ligands, high-mobility group box 1 (HMGB1), were increased
during disease progression in hSOD1G93A mice, with TLR4 and HMGB1 expressed by activated microglia and
astrocytes. hSOD1G93A mice lacking TLR4 showed transient improvements in hind-limb grip strength and significantly
extended survival when compared to TLR4-sufficient hSOD1G93A mice.
Conclusion: These results suggest that enhanced glial TLR4 signalling during disease progression contributes to
end-stage ALS pathology in hSOD1G93A mice.
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Amyotrophic lateral sclerosis (ALS) is an adult onset
neurodegenerative disease, which is characterised by the
irreversible loss of upper and lower motor neurons in
the motor cortex, brainstem and spinal cord [1]. This
selective loss of neurons leads to muscle denervation
and atrophy, resulting in paralysis and eventual death
via respiratory muscle failure [2]. The mechanisms
underlying ALS pathogenesis are still unclear, but an
emerging body of evidence suggests that immune and
inflammatory factors could contribute to the progres-
sion of the disease [3-5]
The toll-like receptor (TLR) system is one of the
major components of the innate immune system, which
has been implicated in ALS pathology. Toll-like* Correspondence: t.woodruff@uq.edu.au
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unless otherwise stated.receptor 4 (TLR4) is a canonical pro-inflammatory TLR
expressed by numerous immune and nonimmune cells,
including cells within the central nervous system [6,7].
TLR4 activation induces the release of cytokines such
as tumour necrosis factor-α and interleukins, which
have been shown to be involved in ALS pathogenesis
[8,9]. Several TLRs, including TLR4, are up-regulated
in hSOD1G93A mice suggesting an involvement in ALS
disease progression [10]. Extracellularly released high-
mobility group box 1 (HMGB1) is an endogenous lig-
and for TLR4, which is shown to translocate from the
nucleus to cytoplasm in reactive astrocytes and acti-
vated microglia cells in ALS patients [11]. In addition,
it was shown that TLR4 antagonism increased motor
function in a spontaneous ‘wobbler’ mouse model of
ALS [8]. However, the specific function of TLR4 in the
most widely used preclinical hSOD1G93A mouse model
of ALS has yet to be reported.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 List of primers used for SYBR Green quantitative PCR
Gene of interest Primer sequence Product length
TLR4 Forward: 5′ - ATGCATGGATCAGAAACTCAGCAA - 3′ 249
Reverse: 5′ - AAACTTCCTGGGGAAAAACTCTGG - 3′
HMGB1 Forward: 5′ - GCTCTCACAGCCATTGCAGTACAT - 3′ 129
Reverse: 5′ - AGGATCTCCTTTGCCCATGTTTAG - 3′
GAPDH Forward: 5′ - AGGTCGGTGTGAACGGATTTG - 3′ 123
Reverse: 5′ - TGTAGACCATGTAGTTGAGGTC - 3′
TLR4, toll-like receptor 4; HMGB1, high-mobility group box 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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the expression of HMGB1 and TLR4 during defined
stages in hSOD1G93A mice. In order to identify the con-
tribution of TLR4 signalling in hSOD1G93A pathogenesis,
we generated hSOD1G93A mice lacking TLR4 and com-
pared them to hSOD1G93A mice in respect to survival
and muscle strength. Our findings demonstrate that lack
of TLR4 signalling has a protective effect on hSOD1G93A
pathology, significantly extending survival and transi-
ently improving motor function.
Methods
Animals
Transgenic hSOD1G93A mice (B6-Cg-Tg (SOD1-G93A)
1Gur/J) were obtained from the Jackson laboratory (Bar
Harbor Maine, USA) and were bred on C57BL/6J back-
ground to produce hSOD1G93A and wild-type (WT)
mice. Female hSOD1G93A and WT mice at four prede-
fined stages of ALS were used in this study as described
previously [12]. Specifically, the predefined stages of dis-
ease progression are: (1) presymptomatic at 30 days
postnatal where no motor deficits are seen, (2) onset at
70 days postnatal where there is initial signs of motor
deficits determined by a significant reduction in hind-
limb grip strength, (3) mid-symptomatic at 130 days
postnatal where there is marked weakness in hind-limbs
and tremor when suspended by the tail, and (4) end-
stage at 150 to 175 days postnatal where there is fullTable 2 Summary of antibodies used for immunohistochemis
Antibody Manufacturer
Rat anti-mouse TLR4 R & D Systems
Rabbit anti-mouse HMGB1 Abcam
Mouse anti-mouse GFAP BD Biosciences
Rabbit anti-mouse Iba-1 Wako
Goat anti-mouse ChAT Chemicon
TLR4, toll-like receptor 4; HMGB1, high-mobility group box 1; GFAP, glial fibrillary ac
adapter molecule-1.paralysis of lower limbs and loss of righting reflex (also
defined as the survival end-point). TLR4−/− female mice
on C57BL/6 background, a gift originally from Dr.
Shizuo Akira, were bred with male hSOD1G93A to yield
hSOD1G93A mice lacking TLR4 (hSOD1G93A × TLR4−/−)
at F2 generation. Female hSOD1G93A and hSOD1G93A ×
TLR4−/− mice were used for all phenotype studies. All
experimental procedures were approved by the University
of Queensland Animal Ethics Committee.Survival analysis, weight measurements and hind-limb
grip strength test
Survival was determined by the inability of the ani-
mal to right itself within 30 s if laid on either side.
This is a widely accepted and published end-point
for life span studies in ALS mice [13,14]. The weight
and hind-limb grip strength of hSOD1G93A and
hSOD1G93A × TLR4−/− mice were measured as de-
scribed previously [12].Quantitative PCR
Gene expression was measured by SYBR Green real-
time PCR (Applied Biosystems, Grand Island, NY, USA)
according to manufacturer’s protocols. All primers used
are listed in Table 1. Final measures are presented as
relative levels of gene expression in hSOD1G93A micetry
Dilution In combination with
1:500 GFAP, Iba-1 and ChAT
1:1,000 GFAP, CD11b and ChAT
1:1,000 TLR4
1:400 TLR4
1:100 TLR4
idic protein; ChAT, choline acetyltransferase; Iba-1, ionised calcium-binding
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ously [12].Western blotting
Lumbar spinal cord homogenates were resolved on a 10%
sodium dodecyl sulphate polyacrylamide gel and electro-
transferred onto nitrocellulose membranes. The mem-
brane was incubated with anti-TLR4 (1:500; Santa Cruz
Biotechnology, Dallas, Texas, USA) or anti-HMGB1
(1:1000; Abcam, Melbourne, Victoria, Australia) antibodies
and were detected with enhanced chemiluminescence
(GE Healthcare, Sydney, New South Wales, Australia).Figure 1 Expression of HMGB1 and TLR4 during disease progression in wil
HMGB1 and TLR4 in the lumbar spinal cord of hSOD1G93A mice relative to
blot of HMGB1 with β-tubulin in the lumbar spinal cord of hSOD1G93A (SOD
HMGB1 determined by semi-quantitative densitometry in the lumbar spina
ages. (D) Representative Western blot of TLR4 with β-tubulin in the lumbar
mice at different ages. Protein expression of TLR4 determined by semi-qua
mice relative to age-matched WT mice at four different ages. Data expresse
(C) and (D); *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test). Dashed line
PS = pre-symptomatic; OS = onset; MS = mid-symptomatic; ES = end-stage
TLR4 = toll-like receptor 4.Densitometric analyses of immunoreactive bands were
quantified as described previously [12].
Immunohistochemistry
Fluorescence double immunolabelling was performed to
localise the expression of TLR4 with specific cell-type
markers for motor neurons, astrocytes and microglia as
described previously [12]. The combination of antibodies
used in this study is outlined in Table 2.
Statistical analysis
Statistical differences between hSOD1G93A and hSO
D1G93A × TLR4−/− mice were analysed using a two-d-type and hSOD1G93A mice. (A) and (B) mRNA expression profile of
wild-type (WT) mice at four disease stages. (C) Representative Western
1) mice relative to WT mice at four disease ages. Protein expression of
l cord of hSOD1G93A (SOD1) mice relative to WT mice at four different
spinal cord of hSOD1G93A (SOD1) mice relative to age-matched WT
ntitative densitometry in the lumbar spinal cord of hSOD1G93A (SOD1)
d as mean ± SEM (n = 9 mice/group (A) and (B); n = 3~4 mice/group
represents the baseline expression in WT mice at each disease stage.
; HMGB1 = high-mobility group box 1; mRNA = messenger RNA;
Figure 2 (See legend on next page.)
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Figure 2 Localization of HMGB1 in wild-type and hSOD1G93A mice at end-stage of disease. (A-R) Double immunolabelling of HMGB1 (red) with
cellular markers (green) for motor neurons (ChAT; (A-C) wild-type (WT) mice, (J-L) hSOD1G93A mice), microglia (CD11b; (D-F) WT mice, (M-O)
hSOD1G93A mice), and astrocytes (GFAP; (G-I) WT mice, (P-R) for hSOD1G93A mice) in the ventral lumbar spinal cord of WT and hSOD1G93A mice
at end-stage of disease. HMGB1 displayed diffuse nuclear staining and was mainly co-localised with CD11b-labelled microglia and GFAP-positive
astrocytes in WT mice (F, I, white arrows), with no co-localisation with ChAT-positive motor neurons (C). In hSOD1G93A mice, HMGB1 immunolabelling
increased in intensity and appeared more punctate and was evident on GFAP-positive astrocytes and CD11b-labelled microglia (white arrows in M, O,
P, R). Similar to WT mice, immunolabelling of HMGB1 was absent from ChAT-positive motor neurons in hSOD1G93A mice (L, white arrow). Scale
bars for all panels = 10 μm. HMGB1 = high-mobility group box 1; ChAT = choline acetyltransferase; CD11b = cluster of differentiation molecule
11B; GFAP = glial fibrillary acidic protein.
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gression and a log-rank test for Kaplan-Meier survival
plots. All data are presented as mean ± SEM and differ-
ences were considered significant when P ≤ 0.05.
Results
HMGB1 and TLR4 are up-regulated during disease
progression in hSOD1G93A mice
We initially examined the mRNA expression of TLR4
and HMGB1 in the lumbar spinal cord during key dis-
ease stages in hSOD1G93A mice. HMGB1 mRNA levels
were increased by 1.7 fold at the end-stage of disease,
compared with WT mice (n = 9, **P < 0.01; Figure 1A).
TLR4 mRNA in hSOD1G93A mice progressively in-
creased by 1.4 fold, 1.6 fold and 5.6 fold at onset,
mid-symptomatic and end-stage, respectively, when
compared to WT mice (n = 9, *P < 0.05 and ***P <
0.001; Figure 1B). At the protein level, HMGB1 protein
expression increased at the end-stage of disease (2.5 fold
increase; n = 4, *P < 0.05; Figure 1C). TLR4 protein ex-
pression was also increased by 2.9 fold at the end-stage
of disease when compared with WT mice (n = 4, *P <
0.05; Figure 1D).
HMGB1 and TLR4 are expressed by ALS-relevant cell
types in hSOD1G93A mice
Next, we immuno-stained the lumbar spinal cords from
hSOD1G93A and WT mice for HMGB1 and TLR4 with
specific cellular markers for motor neurons (anti-cho-
line acetyltransferase(ChAT)), microglia (anti-CD11b/
anti-ionised calcium-binding adapter molecule-1(Iba-
1)) and astrocytes (anti-glial fibrillary acidic protein
(GFAP)). HMGB1 was expressed by CD11b-positive
microglia and GFAP-positive astrocytes in WT (white
arrows in Figure 2F, I) and hSOD1G93A mice (white ar-
rows in Figure 2M, O, P, R). However, HMGB1 did not
significantly co-localise with motor neurons in both
WT and hSOD1G93A mice (white arrows in Figure 2C,L).
By contrast, TLR4 was primarily expressed on motor
neurons in WT mice (white arrows in Figure 3A,C) and
did not co-localise with surrounding Iba-1-positive
microglia (Figure 3D,E,F) or GFAP-positive astrocytes(Figure 3G,H,I). In hSOD1G93A mice, TLR4 was still
expressed by the few remaining motor neurons at the
end-stage of disease (white arrow in Figure 3J,L). How-
ever, as compared to WT mice, in hSOD1G93A mice,
TLR4 was strongly expressed on GFAP-positive astro-
cytes (white arrows in Figure 3P,R) with some localisa-
tion with Iba-1-labelled microglia (white arrows in
Figure 3M,O).hSOD1G93A mice lacking TLR4 transiently improves
hind-limb grip strength and extends survival when
compared to hSOD1G93A mice
Given our findings demonstrating increased expression
of TLR4 and one of its endogenous ligands HMGB1, in
hSOD1G93A mice, we next assessed whether enhanced
TLR4 signalling contributes to disease pathogenesis by
generating hSOD1G93A mice lacking TLR4 (hSOD1G93A ×
TLR4−/−). hSOD1G93A × TLR4−/− mice showed extended
survival when compared to hSOD1G93A mice (median
end-stage of disease, hSOD1G93A = 169 days and
hSOD1G93A × TLR4−/− = 184 days, n = 11, *P < 0.05;
Figure 4A). Concomitant with enhanced survival, there
were significant improvements in hind-limb grip strength
of hSOD1G93A × TLR4−/− mice when compared to
hSOD1G93A mice at 56, 63, 84 and 161 days of age (n = 8
to 9, *P < 0.05, +P < 0.01; Figure 4B). No differences in
body weights were seen between the groups at any age
(data not shown).Discussion
Although the exact mechanisms that underlie the patho-
genesis of ALS remain unclear, there is credible evidence
that a co-ordinated action of innate and adaptive im-
mune factors is involved in the progression of ALS. This
includes evidence for major innate immune systems
such as the complement cascade [12,15] and the toll-like
receptor system [16]. For example, the pathogenic effect
of TLR4 has been observed in the wobbler mouse model
of ALS, where TLR4 antagonism improved disease out-
comes [8]. The present study adds additional support to
a pathogenic role for TLR4 in ALS.
Figure 3 (See legend on next page.)
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Figure 3 Localization of TLR4 in wild-type and hSOD1G93A mice at end-stage of disease. (A-R) Double immunolabelling of TLR4 (red) with cellular
markers (green) for motor neurons (ChAT; (A-C) wild-type (WT) mice, (J-L) hSOD1G93A mice), microglia (Iba-1; (D-F) WT mice, (M-O) hSOD1G93A
mice), and astrocytes (GFAP; (G-I) WT mice, (P-R) for hSOD1G93A mice) in the ventral lumbar spinal cord of WT and hSOD1G93A mice at end-stage
of disease. TLR4 was mainly co-localised with ChAT-positive motor neurons in the WT mice (A, C, white arrow) with minimal co-localisation with
Iba-1-labelled microglia and GFAP-positive astrocytes (F, I). In hSOD1G93A mice, TLR4 immunolabelling was evident on ChAT positive motor
neurons and GFAP-positive astrocytes with some localisation with Iba-1-labelled microglia (white arrows in J, L, M, O, P, R). Scale bars for all
panels = 10 μm. TLR4 = toll-like receptor 4; ChAT = choline acetyltransferase; Iba-1 = ionised calcium-binding adapter molecule-1; GFAP = glial
fibrillary acidic protein.
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cord of hSOD1G93A mice, where it was localised pre-
dominantly to astrocytes and some microglia. Import-
antly, HMGB1, an endogenous cell secreted ligand for
TLR4, was similarly up-regulated and expressed by as-
trocytes and microglia. It is plausible that degenerating
motor neurons and the associated neuroinflammatory
process triggers HMGB1 release from activated astro-
cytes and microglia in hSOD1G93A mice. This, in turn,
could trigger further neuronal death via binding to glia-
expressed TLR4 to release additional neurotoxic factors,
although this hypothesis is yet to be tested in this dis-
ease model. In support of this, activation of TLR4 on
microglia and astrocytes can trigger different signalling
pathways that lead to the production of pro-inflammatory
mediators including cytokines, nitric oxide and reactive
oxygen species [17]. Taken together, this suggests that
TLR4 signalling could be an additional player in the pro-
inflammatory reactions that exacerbate disease progres-
sion in ALS, as shown previously in ischemic stroke [18]
and Alzheimer’s disease [19].
To identify the role TLR4 plays in ALS disease pro-
gression, we generated hSOD1G93A mice lacking TLR4Figure 4 hSOD1G93A mice lacking TLR4 (hSOD1G93A × TLR4−/−) have exten
compared to hSOD1G93A mice. (A) shows a Kaplan-Meier plot of ages (in d
fully deleted (TLR4−/−, blue line) TLR4 reached the end-stage of disease (co
on its back). hSOD1G93A × TLR4−/− shows a significant extension in survival
(B) shows hind-limb grip strength in these two groups. A small overall imp
versus hSOD1G93A mice, with significant differences observed at 56, 63, 84
Data are expressed as mean ± SEM.(hSOD1G93A × TLR4−/−). We observed that deletion of
the TLR4 gene in hSOD1G93A mice significantly extended
survival when compared to hSOD1G93A mice expressing
TLR4. This was accompanied by significant improvements
in hind-limb grip strength at select time points. This sup-
ports the hypothesis that enhanced TLR4 signalling con-
tributes to ALS progression and that this effect likely
occurs through increased activation of microglia and as-
trocytes [8,20]. It should be noted however, that the extent
of survival extension, and motor functional improvements
in hSOD1G93A mice were moderate, indicating that TLR4
is but one of many contributors to hSOD1G93A ALS dis-
ease pathogenesis.
In summary, the present study has demonstrated that
deletion of TLR4 significantly extends survival and tran-
siently improves hind-limb grip strength in an ALS dis-
ease model, suggesting that TLR4 signalling in these
animals may contribute to motor neuron death and ul-
timately disease progression of ALS. Hence, this study
suggests that reducing downstream consequences of
TLR4 activation through specific inhibitors should be
further explored as one potential therapeutic strategy to
slow disease progression in ALS.ded survival and improvements in hind-limb grip strength when
ays) in which hSOD1G93A mice with normal (TLR4+/+, red line) or
mplete hind-limb paralysis and an inability to right itself once placed
time relative to hSOD1G93A mice (n = 11, P < 0.05, log-rank test).
rovement in grip strength was seen in hSOD1G93A × TLR4−/− mice
and 161 days of age (n = 8–9, *P < 0.05, +P < 0.01, Student’s t-test).
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